Philip D Home
Overview
Explore the profile of Philip D Home including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1979
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Home P
Diabetes Obes Metab
. 2025 Mar;
PMID: 40035222
Nearly all health professionals, whatever their practice or speciality, now have contact with a significant number of insulin-using people with diabetes. People with type 1 diabetes are nearly universally managed...
2.
Home P, McCrimmon R, Rosenstock J, Bluher M, Pegelow K, Melas-Melt L, et al.
Diabetes Obes Metab
. 2022 Oct;
25(3):656-663.
PMID: 36309941
Aim: To report prespecified and post hoc analyses of the SoliMix dataset exploring the impact of baseline participant characteristics on the original SoliMix study outcomes, to enable informed treatment choices...
3.
4.
Home P, Mehta R
Lancet Diabetes Endocrinol
. 2021 Sep;
9(10):695-707.
PMID: 34480874
The first insulin preparation capable of consistently lowering blood glucose was developed in 1921. But 100 years later, blood glucose control with insulin in people with diabetes is nearly universally...
5.
Home P, Mehta R, Hafidh K, Gurova O, Alvarez A, Serafini P, et al.
Diabetes Obes Metab
. 2021 Aug;
23(12):2660-2669.
PMID: 34402153
Aim: To assess the efficacy and safety of iGlarLixi, a fixed-ratio combination of basal insulin glargine 100 U/mL and lixisenatide (glucagon-like peptide-1 receptor agonist) versus IDegAsp, a co-formulation of basal...
6.
Home P, Aroda V, Blonde L, Guyot P, Shaunik A, Fazeli M, et al.
Diabetes Obes Metab
. 2020 Jul;
22(11):2170-2178.
PMID: 32627297
Aims: To estimate the relative treatment effect between the fixed-ratio combinations iGlarLixi and IDegLira (glucagon-like peptide 1 receptor agonist with basal insulin) in people with type 2 diabetes inadequately controlled...
7.
Lu J, Home P, Zhou J
Diabetes Care
. 2020 Jun;
43(8):e99-e101.
PMID: 32527796
No abstract available.
8.
Bolli G, Landgraf W, Bosnyak Z, Melas-Melt L, Home P
Diabetes Obes Metab
. 2020 Apr;
22(9):1664-1669.
PMID: 32314521
The relationship between baseline fasting C-peptide (FCP) and glucose control was examined in insulin-naïve people with type 2 diabetes inadequately controlled with oral antihyperglycaemic drugs commencing basal insulin glargine 300 ...
9.
Owens D, Landgraf W, Frier B, Zhang M, Home P, Meneghini L, et al.
Diabetes Obes Metab
. 2018 Dec;
21(2):321-329.
PMID: 30520217
Aims: To identify factors associated with achievement of glycated haemoglobin A1c (HbA1c) target at 24 weeks after commencing basal insulin therapy in individuals with type 2 diabetes mellitus (T2DM). Materials...
10.
Home P, Lam R, Carofano W, Golm G, Eldor R, Crutchlow M, et al.
Diabetes Obes Metab
. 2018 May;
20(9):2220-2228.
PMID: 29766635
Aim: To compare the efficacy and safety of MK-1293 insulin glargine (Mk-Gla; 100 U/mL) with originator insulin glargine, Lantus (Sa-Gla), in people with type 1 diabetes mellitus (T1DM). Materials And...